Clinical decisions on whether to prescribe a novel biologic or a biosimilar may be driven, in part, by the condition and stage of disease, representatives from the pharmacy benefit, patient and clinician communities say.
“In terms of interchangeability, substitutability, similarity, it could very well depend upon the disease state,” said Jeff Eichholz, senior director...